CD33 and acute myeloid leukemia: Results of a recent Children’s Oncology Group randomized clinical trial of GO in children with newly diagnosed AML suggest that patients with the CC genotype for rs12459419 have a substantial response to GO, an observation which points to CD33 polymorphisms as potential biomarkers for the selection of patients with greatest likelihood of significant response to immunotherapy with GO [153].